LINDSAY A MCNAIR, M.D.
Osteopathic Medicine at Waverly St, Cambridge, MA
License number
Massachusetts 204795
Category
Osteopathic Medicine
Type
General Practice
Address
Address
2
130 Waverly St, Cambridge, MA 02139
10 Bagnal St, Boston, MA 02134
10 Bagnal St, Boston, MA 02134
Phone
(617) 444-6535
Organization information
See more information about LINDSAY A MCNAIR at bizstanding.comLindsay A Mcnair, MD
130 Waverly St, Cambridge, MA 02139
Industry:
Family Doctor
Doing business as:
Lindsay McNair MD
Phone:
(617) 444-6535 (Phone)
Lindsay Anne Mcnair
Professional information
Principal And Owner At Equipoise Consulting, Llc
Location:
Greater Boston Area
Industry:
Pharmaceuticals
Dr. Lindsay A Mcnair, Allston MA - MD (Doctor of Medicine)
Specialties:
General Surgery
Address:
12 Bagnal St, Allston 02134
(617) 782-3698 (Phone)
130 Waverly St, Cambridge 02139
(617) 444-6535 (Phone)
(617) 782-3698 (Phone)
130 Waverly St, Cambridge 02139
(617) 444-6535 (Phone)
Languages:
English
Education:
Medical School
Univ Of Ct Sch Of Med
Graduated: 1995
Univ Of Ct Sch Of Med
Graduated: 1995
Treatment Of Hepatitis C Virus With Telaprevir (Vx-950) In Patients Non-Responsive To Treatment With Pegylated Interferon-Alpha 2A/2B And Ribavirin
US Patent:
2012004, Feb 23, 2012
Filed:
Jun 3, 2011
Appl. No.:
13/153199
Inventors:
Lindsay McNair - Allston MA, US
John McHutchison - Woodside CA, US
John McHutchison - Woodside CA, US
Assignee:
Vertex Pharmaceuticals Incorporated - Cambridge MA
International Classification:
A61K 38/21, A61P 37/04, A61P 31/14, A61K 38/07, A61K 38/22
US Classification:
424 855, 514 43, 424 856, 424 857, 4242781, 424 854
Abstract:
The present invention relates to antiviral therapies and compositions for treating or preventing Hepatitis C infections in patients and relates to other methods disclosed herein. The invention also relates to kits and pharmaceutical packs comprising compositions and dosage forms. The invention also relates to processes for preparing these compositions, dosages, kits, and packs.
Hcv Combination Therapies Comprising Pegylated Interferon, Ribavirin And Telaprevir
US Patent:
2012003, Feb 16, 2012
Filed:
Aug 11, 2011
Appl. No.:
13/207773
Inventors:
Lindsay McNair - Allston MA, US
Robert S. Kauffman - Chestnut Hill MA, US
John J. Alam - Cambridge MA, US
Ramon Polo - Basking Ridge NJ, US
Gaston Rafael Picchio - Flemington NJ, US
Maria Gloria Beumont - Issy Les Moulineaux, FR
Robert S. Kauffman - Chestnut Hill MA, US
John J. Alam - Cambridge MA, US
Ramon Polo - Basking Ridge NJ, US
Gaston Rafael Picchio - Flemington NJ, US
Maria Gloria Beumont - Issy Les Moulineaux, FR
Assignee:
Janssen Pharmaceutica NV - Beerse
Vertex Pharmaceuticals Incorporated - Cambridge MA
Vertex Pharmaceuticals Incorporated - Cambridge MA
International Classification:
A61K 38/21, A61P 31/14
US Classification:
424 857, 424 854
Abstract:
The invention relates to combination therapies for the treatment of hepatitis C virus with telaprevir and pegylated interferon alfa-2a with or without ribavirin. The invention relates to the treatment of patients with bridging fibrosis infected with HCV using the combination therapy.
Dose Forms Comprising Vx-950 And Their Dosage Regimen
US Patent:
2010018, Jul 29, 2010
Filed:
Nov 20, 2009
Appl. No.:
12/592225
Inventors:
Lindsay McNair - Allston MA, US
Robert S. Kauffman - Chestnut Hill MA, US
John J. Alam - Cambridge MA, US
Bambang S. Adiwijaya - Belmont MA, US
Varun Garg - Framingham MA, US
Ann D. Kwong - Cambridge MA, US
Tara L. Kieffer - Brookline MA, US
Robert S. Kauffman - Chestnut Hill MA, US
John J. Alam - Cambridge MA, US
Bambang S. Adiwijaya - Belmont MA, US
Varun Garg - Framingham MA, US
Ann D. Kwong - Cambridge MA, US
Tara L. Kieffer - Brookline MA, US
Assignee:
VERTEX PHARMACEUTICALS INCORPORATED - Cambridge MA
International Classification:
A61K 38/21
US Classification:
424 857, 424 854
Abstract:
The present invention relates to antiviral therapies and compositions for treating or preventing Hepatitis C infections in patients and relates to other methods disclosed herein. The invention also relates to kits and pharmaceutical packs comprising compositions and dosage forms. The invention also relates to processes for preparing these compositions, dosages, kits, and packs.
Hcv Combination Therapies
US Patent:
2010022, Sep 9, 2010
Filed:
May 4, 2010
Appl. No.:
12/773364
Inventors:
Lindsay McNair - Allston MA, US
Assignee:
VERTEX PHARMACEUTICALS INCORPORATED - Cambridge MA
International Classification:
A61K 38/21, A61P 31/12
US Classification:
424 857
Abstract:
The invention relates to combination therapies for the treatment of hepatitis C virus with telaprevir and pegylated interferon alfa-2a with or without ribavirin. The invention relates to the treatment of Latino and African American patients infected with HCV using the combination therapy.
Dose Forms
US Patent:
2006010, May 18, 2006
Filed:
Oct 31, 2005
Appl. No.:
11/264746
Inventors:
Hui-May Chu - Natick MA, US
Ene Ette - Framingham MA, US
Lindsay McNair - Allston MA, US
John Alam - Cambridge MA, US
Ene Ette - Framingham MA, US
Lindsay McNair - Allston MA, US
John Alam - Cambridge MA, US
International Classification:
A61K 31/70, A61K 39/12, A01N 43/04
US Classification:
514044000, 424204100
Abstract:
The present invention relates to antiviral therapies and compositions for treating or preventing Hepatitis C infections in patients and relates to other methods disclosed herein. The invention also relates to kits and pharmaceutical packs comprising compositions and dosage forms. The invention also relates to processes for preparing these compositions, dosages, kits, and packs.